Buckmiller Lisa M, Francis Carrie L, Glade Robert S
Vascular Anomalies Center, University of Arkansas for Medical Sciences, Arkansas, Children's Hospital, Little Rock, AR, USA.
Int J Pediatr Otorhinolaryngol. 2008 Jan;72(1):81-7. doi: 10.1016/j.ijporl.2007.09.024. Epub 2007 Dec 3.
To evaluate the efficacy of proliferative phase intralesional steroid injections in the treatment of parotid hemangiomas.
Retrospective analysis of pediatric patients with parotid hemangiomas treated with intralesional steroid injections during the proliferative phase.
Vascular Anomalies Center, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USA.
Twenty-one pediatric patients, ages 4-39 months.
Between 2001 and 2006, 21 patients received steroid injections for 23 parotid hemangiomas (bilateral in 2 patients). A total of 1-3 injections over the first year of life were given at 6-25 week intervals.
Main outcome measures included softening, decreased growth rate, and/or decrease in size. After injection, achievement of outcome measures occurred with all lesions. No incidence of tissue atrophy or facial nerve injury was seen. Four of 21 (19%) patients developed failure to thrive (FTT).
Parotid hemangiomas can be effectively controlled with proliferative phase intralesional steroid injections. Injections may limit the need for future extensive surgery. Further prospective randomized trials are needed to support these claims. Failure to thrive may be a potential complication of intralesional steroid injection. Endocrine/growth monitoring should be considered when treating with intralesional steroids.
评估增殖期病灶内注射类固醇治疗腮腺血管瘤的疗效。
对增殖期接受病灶内注射类固醇治疗的腮腺血管瘤患儿进行回顾性分析。
美国阿肯色州小石城阿肯色大学医学科学学院血管异常中心、阿肯色儿童医院。
21例年龄在4至39个月的儿科患者。
2001年至2006年期间，21例患者因23处腮腺血管瘤（2例为双侧）接受类固醇注射。在生命的第一年，每隔6至25周共注射1至3次。
主要观察指标包括软化、生长速度减慢和/或体积减小。注射后，所有病灶均达到观察指标。未观察到组织萎缩或面神经损伤的发生。21例患者中有4例（19%）出现生长发育迟缓。
增殖期病灶内注射类固醇可有效控制腮腺血管瘤。注射可能减少未来进行广泛手术的必要性。需要进一步的前瞻性随机试验来支持这些结论。生长发育迟缓可能是病灶内注射类固醇的潜在并发症。使用病灶内类固醇治疗时应考虑进行内分泌/生长监测。
Zotero 插件